BNB Plus (BNBX)
NASDAQ:BNBX
Want to see BNBX full AI Analyst Report?
Top Page
BNB Plus
(NASDAQ:BNBX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.45
▼(-69.73% Downside)
Action:UpgradedDate:05/12/26
The score is driven primarily by weak financial performance (shrinking revenue, deep losses, and ongoing cash burn), reinforced by bearish technical trends (price below key moving averages with negative MACD). Valuation offers limited support due to losses (negative P/E) and no dividend yield, and delisting risk further increases downside uncertainty.
Positive Factors
Low leverage
The balance sheet shows virtually no debt (debt-to-equity ~0.00), reducing refinancing and near-term solvency risk. This durable strength provides financial flexibility while the company navigates losses, lowering probability of immediate creditor pressure over the next several months.
Negative Factors
Shrinking revenue
TTM revenue declined ~23.5%, indicating loss of scale and weakening demand. Persistent top-line contraction undermines ability to spread fixed costs, threatens margins, and makes sustainable profitability harder without successful product or commercial recovery over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The balance sheet shows virtually no debt (debt-to-equity ~0.00), reducing refinancing and near-term solvency risk. This durable strength provides financial flexibility while the company navigates losses, lowering probability of immediate creditor pressure over the next several months.
Read all positive factors
BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.75M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)2.62
Revenue Growth-45.07%
EPS Growth93.71%
CountryUS
Employees46
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-269.50
Shares Outstanding5,667,469
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.65
Enterprise Value/Revenue-0.86
Enterprise Value/Gross Profit-3.74
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-82.5
Revenue Forecast (FY)$7.40M
BNB Plus Business Overview & Revenue Model
Company Description
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Product...
How the Company Makes Money
null...
BNB Plus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.05M | 2.14M | 3.43M | 13.37M | 18.17M | 9.03M |
| Gross Profit | 474.56K | 838.91K | 1.02M | 5.53M | 5.05M | 4.93M |
| EBITDA | -26.27M | -15.66M | -13.33M | -9.59M | -12.68M | -11.68M |
| Net Income | -31.11M | -15.16M | -6.99M | -9.95M | -8.38M | -16.03M |
Balance Sheet | ||||||
| Total Assets | 20.70M | 4.44M | 12.79M | 13.65M | 22.27M | 14.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.45M | 1.67M | 6.43M | 7.15M | 15.22M | 6.55M |
| Total Debt | 48.86K | 193.25K | 739.16K | 1.24M | 0.00 | 0.00 |
| Total Liabilities | 2.24M | 2.50M | 3.82M | 8.78M | 9.36M | 3.30M |
| Stockholders Equity | 18.84M | 2.30M | 9.14M | 4.95M | 12.91M | 11.11M |
Cash Flow | ||||||
| Free Cash Flow | -15.12M | -12.83M | -14.12M | -6.30M | -9.47M | -15.94M |
| Operating Cash Flow | -14.92M | -12.52M | -13.71M | -6.22M | -8.98M | -13.39M |
| Investing Cash Flow | -3.14M | -292.12K | -407.90K | -1.10M | -489.55K | -2.55M |
| Financing Cash Flow | 11.06M | 8.05M | 13.40M | 0.00 | 18.13M | 14.70M |
BNB Plus Technical Analysis
Negative
1.48
Price Trends
0.72
Negative
1.39
Negative
2.63
Negative
Market Momentum
-0.06
Negative
35.95
Neutral
28.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.72, and below the 200-day MA of 2.63, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 35.95 is Neutral, neither overbought nor oversold. The STOCH value of 28.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.
BNB Plus Risk Analysis
BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BNB Plus Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
49 Neutral | $6.14M | -0.28 | -537.60% | ― | ― | 99.05% | |
46 Neutral | $4.72M | -0.85 | -197.93% | ― | 18.14% | 56.57% | |
41 Neutral | $2.75M | -0.15 | -259.18% | ― | -45.07% | 93.71% | |
41 Neutral | $6.74M | -0.06 | -496.37% | ― | -79.24% | 88.08% |
* Financial Sector Average
BNBX
BNB Plus
0.47
-11.98
-96.23%
NDRA
ENDRA Life Sciences
5.05
1.60
46.38%
INBS
Intelligent Bio Solutions
3.14
-9.06
-74.26%
ISPC
iSpecimen
5.05
-41.75
-89.21%
BGLC
BioNexus Gene Lab Corp
2.06
-1.01
-32.90%
BNB Plus Corporate Events
Shareholder MeetingsStock Split
BNB Plus Shareholders Approve Board Reverse Split Authority
Neutral
Apr 29, 2026
On April 28, 2026, BNB Plus Corp. held a special meeting of stockholders at which investors approved granting the board of directors 12-month discretionary authority to implement a reverse stock split at a ratio between one-for-five and one-for-th...
Delistings and Listing ChangesRegulatory Filings and Compliance
BNB Plus Faces Nasdaq Delisting Risk After Bid Price Breach
Negative
Mar 24, 2026
BNB Plus Corp. disclosed that on March 20, 2026, it received a notice from Nasdaq stating that the company no longer meets the minimum $1.00 bid price requirement for continued listing, after its shares traded below that threshold for 30 consecuti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.